The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Prostate Cancer Patients Clinical Trial

Official title:
A Single-center, Open-label, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Midazolam （CYP3A4 Substrates), S-Warfarin (CYP2C9 Substrates) and Omeprazole (CYP2C19 Substrates) in Prostate Cancer Patients

Status Completed

Clinical Trial Summary

The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04676035
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	June 15, 2020
Completion date	January 26, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03795207` - Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)	Phase 2
Completed	`NCT02715583` - C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer	Early Phase 1
Recruiting	`NCT04664725` - Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion	Phase 1
Recruiting	`NCT03258320` - A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis	Phase 1